Clinical trial Recruiting at 1 site Phase 4 Interventional Ages 12 to 17

Pharmacogenetically-guided treatment for anxiety in kids

Official title: Pharmacogenetically-guided Escitalopram Treatment for Pediatric Anxiety: Aiming to Improve Safety and Efficacy (PrEcISE)

Run by University of Cincinnati · NCT04623099 · Data updated 2026-11-12

This study is testing if adjusting anxiety medication based on kids' genetics helps them feel better compared to standard dosing.

Quick facts

PhasePhase 4
Study typeInterventional
Ages12 Years to 17 Years
SexAll
Enrollment132 (estimated)
SponsorUniversity of Cincinnati
Academic / other
Locations1 site (Cincinnati, Ohio)
StatusRecruiting
StartedMarch 8, 2021
Main results expectedJune 30, 2026
Study endsDecember 1, 2026
Registry record updatedAugust 29, 2024
Trial IDNCT04623099 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are adolescents aged 12-17 diagnosed with generalized, social, or separation anxiety disorders.

Probably not a fit

Patients who do not meet the diagnostic criteria for anxiety disorders or those currently undergoing psychotherapy may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This double-blind, 12-week clinical trial will involve 132 adolescents aged 12-17 with anxiety disorders, who will be randomized to receive either standard or pharmacogenetically-guided dosing of escitalopram. The study aims to compare the efficacy and tolerability of these two dosing strategies. Participants will be evaluated for their response to treatment using established clinical measures. The goal is to determine if personalized dosing based on genetic factors can improve treatment outcomes for anxious youth.

Why it matters

Potential benefit: If successful, this approach could lead to more effective and safer anxiety treatment options for children and adolescents.

How similar studies have gone: Other studies have shown promise in pharmacogenetically-guided treatments, suggesting potential for success in this approach.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. Written, informed assent and consent.
2. Patients, parent/guardian must be fluent in the English.
3. 12 to 17 years of age, inclusive, at Visit 1.
4. Patients must meet DSM-512 criteria for generalized, social and/or separation anxiety disorder, confirmed by the MINI-KID.
5. PARS score ≥15 at Visit 1 and Visit 2.
6. No initiation of psychotherapy within 8 weeks of screening (Visit 1). Current therapy much be stable for ≥2 months prior to baseline (Visit 2).
7. Clinical Global Impressions-Severity (CGI-S) score ≥4 at Visits 1 \& 2.
8. Caregiver who is willing to consent to be responsible for safety monitoring of the patient, provide information about the patient's condition, oversee the administration of the investigational product.
9. No clinically significant abnormalities on physical examination and EKG.
10. Negative pregnancy test at Visit 1 in females.
11. Negative urine drug screen at Visit 1.
12. Sexually active patients must practice a reliable method of contraception that will continue for the duration of the study and for a minimum of 30 days following the end of study participation. Reliable methods of contraception are defined below; other forms of contraceptives (pharmacological and/or non-pharmacological) are not accepted:

    1. Surgical sterilization
    2. Oral contraceptives (e.g. estrogen-progestin combination or progestin)
    3. Transdermally-delivered contraceptives (e.g., Ortho-Evra), depot injections (e.g., Depo-Provera)
    4. Vaginal contraceptive ring (e.g., NuvaRing), contraceptive implants (e.g., Implanon, Norplant II/Jadelle)
    5. An intrauterine device
    6. Diaphragm plus condom. -

Exclusion Criteria:

1. Co-occurring DSM-5 mood disorder (except persistent depressive disorder, unspecified depressive disorder, provided that the primary diagnosis is an anxiety disorder), eating, bipolar or psychotic disorders.
2. A lifetime diagnosis of an intellectual disability.
3. A significant history of trauma exposure.
4. A history of SSRI treatment within 12 weeks of baseline or current treatment with a medication with psychiatric effects that requires \>5 half-lives for washout History of non-response to \>2 SSRIs.
5. Allergy, intolerance, non-response or hypersensitivity to escitalopram. Major neurological or medical illness or head trauma with ≥5 minutes loss of consciousness.
6. Alcohol or substance use disorder within the past 6 months (nicotine use is permitted).
7. Psychotherapy initiated within 8 weeks of screening (Visit 1), or plans to initiate/change therapy during the study.
8. Pregnant, breastfeeding, lactating, and/or planning to become pregnant during the study or within 30 days following the end of study participation.
9. Positive urine pregnancy test.
10. A positive urine drug screen.
11. Patient lives \>90 minutes from UC or unable to attend follow-up visits. Suicide risk as determined by either: (1) any suicide attempt within the past 6 months and/or (2) significant risk at Visit 1 (Screening) or Visit 2 (Baseline), as judged by the Investigator.
12. QTc \>450 in males or \>460 in females (prolonged QTc based on American Heart Association recommendations for Standardization and Interpretation of the EKG
13. Patients who are unable to swallow capsules.

Where it's running

  • University of Cincinnati, Department of Psychiatry & Behavioral Neuroscience
    Cincinnati, Ohio, United States
    Recruiting

Study contacts

  • Principal investigator: Jeffrey R Strawn, MD — University of Cincinnati
  • Study coordinator: Zoe Neptune, BS
  • Email: neptunza@uc.edu
  • Phone: (513) 558-2866

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.